A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 11 May 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
    • 30 Sep 2010 Results were presented at the 23rd Scientific Meeting of the International Society of Hypertension.
    • 01 May 2010 Results were presented at the 25th Annual Scientific Meeting of the American Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top